Core Viewpoint - A lawsuit has been filed against Civitas Resources, Inc. and its senior executives for potential violations of federal securities laws, alleging misleading statements regarding the company's production capabilities and costs [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Lin v. Civitas Resources, et al., No. 25-cv-03791, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 1, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - Civitas Resources is an oil and gas exploration and production company with key assets in the Denver-Julesburg Basin in Colorado and the Permian Basin in Texas and New Mexico [3]. - The company claimed to have "enhanced recovery potential" and reduced operating costs, but the lawsuit alleges that actual production peaked in 2024, requiring significant capital for further production [3]. Group 3: Stock Performance - Following the announcement of disappointing Q4 and full year 2024 results on February 24, 2025, Civitas's stock price fell over 18%, from $49.30 to $40.35 per share [4]. - The company also announced a 10% workforce reduction and the immediate firing of its Chief Operating Officer and Chief Transformation Officer [4].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's performance and treatment timelines for its melanoma drug Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Performance - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, administering it at authorized treatment centers (ATCs) [3]. - The company has faced challenges with ATCs, including long timelines for patient treatment initiation and ineffective patient identification, leading to high patient drop-off rates [4]. Financial Impact - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward, citing slow treatment timelines and high patient drop-off rates as contributing factors [5]. - Following the announcement of poor financial results, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].

Core Viewpoint - A lawsuit has been filed against Compass Diversified Holdings and its executives for potential violations of federal securities laws, stemming from material misstatements in financial statements related to its subsidiary, Lugano Holdings, Inc. [1][3] Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Matthews v. Compass Group Diversified Holdings, Inc., et al., No. 25-cv-981 [2] - Investors have until July 8, 2025, to request to be appointed to lead the case [2] Group 2: Financial Misstatements - Compass admitted that its fiscal 2022-2024 financial statements contained material misstatements regarding unrecorded financing arrangements and irregularities in sales, cost of sales, inventory, and accounts receivable for Lugano [3] - On May 7, 2025, Compass announced that investors should not rely on its fiscal 2024 financial statements due to an ongoing internal investigation, leading to a significant stock price decline of approximately 62% [4] - On June 25, 2025, Compass further advised that investors should not rely on its fiscal 2022 and 2023 financial statements amid the ongoing investigation [5] Group 3: Stock Performance - Following the announcement on May 7, 2025, Compass's stock price fell from $17.25 per share to $6.55 per share within a day [4]

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4]. Company Overview - Organon develops and delivers health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon concealed material information about its capital allocation priorities, particularly regarding the future of its quarterly dividend payout [4]. - It is alleged that Organon's reports on dividend payouts being a "number one priority" were misleading, as they were offset by a newly implemented debt reduction strategy, resulting in a more than 70% decrease in the quarterly dividend [4]. - Following the acquisition of Dermavant Sciences Ltd., Organon prioritized debt reduction, which further impacted its dividend strategy [4]. Financial Impact - On May 1, 2025, Organon reported first quarter 2025 financial results and announced a drastic reduction in its dividend payout from $0.28 to $0.02, causing its stock price to fall by over 27% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

Group 1 - Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to Carisma Therapeutics Inc.'s merger with OrthoCellix, Inc., where existing Carisma shareholders are expected to own approximately 10% of the combined company [1] - Enzo Biochem, Inc. is being sold to Battery Ventures for $0.70 per share in cash, while Guaranty Bancshares, Inc. is being sold to Glacier Bancorp, Inc. for 1.0000 share of Glacier stock for each Guaranty share [2] - Halper Sadeh LLC may seek increased consideration for shareholders and additional disclosures concerning the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options, with the firm representing investors globally who have experienced securities fraud and corporate misconduct [4]

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Vestis Corporation (NYSE:VSTS) securities between May 2, 2024 and May 6, 2025. Vestis is a North American company that provides uniform rentals and workplace supplies across the U.S. and Canada. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigati ...

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegatio ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased securities of Sarepta Therapeutics, Inc. during the specified Class Period from June 22, 2023, to June 24, 2025, due to alleged misleading statements regarding the safety and efficacy of their gene therapy product, ELEVIDYS [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Sarepta Therapeutics made false and misleading statements about ELEVIDYS, a gene therapy for Duchenne muscular dystrophy, which posed significant safety risks and failed to detect severe side effects [5]. - The lawsuit alleges that the adverse events from ELEVIDYS treatment would lead to a halt in recruitment and dosing in trials, attract regulatory scrutiny, and increase risks around the therapy's approvals [5]. - Investors are encouraged to join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by August 25, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Reddit, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Financial Performance - On May 1, 2025, Reddit reported its financial results for Q1 2025, marking its third consecutive quarter of declining daily active user growth [3]. - Following the Q1 report, Reddit's stock price fell by $4.96 per share, or 4.18%, closing at $113.83 on May 2, 2025 [3]. Analyst Downgrades - On May 19, 2025, Wells Fargo analysts downgraded Reddit's stock, citing concerns over new AI features implemented by Google Search that could disrupt user traffic, resulting in a stock price drop of $5.24 per share, or 4.63%, to close at $107.99 on May 10, 2025 [4]. - On May 21, 2025, Baird analysts also downgraded Reddit's stock for similar reasons, leading to a further decline of $9.79 per share, or 9.27%, closing at $95.85 on May 21, 2025 [5].

NEW YORK, June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lineage, Inc. ("Lineage" or the "Company") (NASDAQ: LINE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Lineage and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action]On or around July 25, 2024, Li ...